Research Library › Neuropeptides
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide of the secretin and glucagon family, found in nerves of the gut, brain and other tissues. Sami Said and Viktor Mutt first isolated it from pig small intestine in 1970 and reported its sequence in 1974. As of October 2026 no VIP product is FDA-approved, and the FDA lists VIP in Category 1 (under evaluation) of its compounding nominations.
Key facts
| Type | Endogenous linear neuropeptide, 28 amino acids |
|---|---|
| Other names | Aviptadil (international nonproprietary name for synthetic VIP) |
| First described | 1970, isolated from porcine small intestine; sequence published 1973–1974 |
| Developed by | Discovered by Sami I. Said and Viktor Mutt (Karolinska Institutet, Stockholm) |
| Designed target | VPAC1 and VPAC2 receptors, G protein-coupled receptors shared with PACAP |
| Regulatory status (Oct 2026) | Not FDA-approved; FDA compounding Category 1 (under evaluation, list updated May 2026); aviptadil combination product authorized in the UK and some European countries |
Who developed it
VIP was discovered rather than designed. The American physician-scientist Sami I. Said worked with the Swedish biochemist Viktor Mutt at the Karolinska Institutet in Stockholm. In 1970 they reported isolating a new polypeptide from the wall of the pig small intestine [1]. Two years later the same team described its purification in more detail.
The name records where the peptide was first found (the intestine) and the vascular activity seen in the original laboratory assays. VIP was later also found in nerve cells of the brain and peripheral nervous system, which is why it is now usually grouped with the neuropeptides. Said remained one of the leading figures in VIP research for decades and was a member of the 1998 committee that named its receptors [2].
Structure and design
VIP is a linear chain of 28 amino acids with an amidated C-terminus. Mutt and Said published the full amino acid sequence of the porcine peptide in 1974 [3]. The sequence places VIP in the secretin and glucagon family of peptide hormones, and it is closely related to PACAP (pituitary adenylate cyclase-activating polypeptide) [2].
VIP binds two receptors, which a 1998 International Union of Pharmacology committee named VPAC1 and VPAC2. Both are G protein-coupled receptors that also bind PACAP, while a third receptor, PAC1, prefers PACAP [2]. A synthetic form of the human peptide has the nonproprietary name aviptadil.
Research history
- 1970: Said and Mutt report isolating VIP from porcine small intestine [1]
- 1974: Full amino acid sequence of porcine VIP published [3]
- 1998: IUPHAR committee names the VPAC1, VPAC2 and PAC1 receptors [2]
- 2017: Scottish Medicines Consortium accepts an aviptadil–phentolamine product for restricted use [4]
- November 2021: FDA declines an emergency use authorization request for aviptadil [5]
Aviptadil has been studied in several clinical programs. In 2021 NRx Pharmaceuticals asked the FDA for an emergency use authorization for its aviptadil product, Zyesami, in a research program on respiratory failure in critical COVID-19; the FDA declined the request, citing inadequate evidence [5].
Regulatory status as of October 2026
No VIP or aviptadil product is approved by the FDA. In the FDA’s list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, vasoactive intestinal peptide appears in Category 1, substances under evaluation [6]. Category 1 placement is not an approval and is not a finding of safety or effectiveness.
Outside the US, aviptadil combined with phentolamine (brand name Invicorp, marketing authorization holder Evolan Pharma AB) is authorized in the United Kingdom and some European countries for an indication related to erectile dysfunction. The Scottish Medicines Consortium accepted it for restricted use in December 2017 [4].
About this reference page
Kalibra Labs does not currently supply VIP (vasoactive intestinal peptide). This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who discovered vasoactive intestinal peptide?
Sami I. Said and Viktor Mutt isolated VIP from pig small intestine at the Karolinska Institutet and reported it in 1970 [1].
How many amino acids are in VIP?
VIP is a 28-amino-acid peptide. Its full sequence was published by Mutt and Said in 1974 [3].
Is VIP FDA approved?
No. As of October 2026 no VIP or aviptadil product is FDA-approved. The FDA lists VIP in Category 1 (under evaluation) of its 503A compounding nominations, which is not an approval [5, 6].
What is aviptadil?
Aviptadil is the nonproprietary name for synthetic VIP. A combination of aviptadil and phentolamine is authorized in the UK and some European countries [4].
What receptors does VIP bind?
VIP binds the VPAC1 and VPAC2 receptors, which it shares with the related peptide PACAP [2].
Sources
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217–1218. Link
- Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 1998;50(2):265–270. Link
- Mutt V, Said SI. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur J Biochem. 1974;42(2):581–589. Link
- Scottish Medicines Consortium. Aviptadil/phentolamine mesilate (Invicorp), SMC 1284/17, advice issued 11 December 2017 (Evolan Pharma AB). Link
- Pharmaceutical Technology. FDA declines EUA for NRx's Zyesami to treat Covid-19 patients. 5 Nov 2021. Link
- U.S. FDA. Bulk drug substances nominated for use in compounding under section 503A, Categories 1–3 (updated 14 May 2026). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
